ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Results of Operations and Financial Condition

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operations and Financial Conditions.

On March 5, 2018, Anthera Pharmaceuticals, Inc. (the “Company”) issued its fourth quarter and year ended December 31, 2017 press release. A copy of the press release is furnished herewith as Exhibit 99.1

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated March 5, 2018


Anthera Pharmaceuticals Inc Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Provides Business Update and Reports 2017 Fourth Quarter and Fiscal Year Financial Results   · RESULT study reported positive interim futility analyses and completion of dosing,…
To view the full exhibit click here

About ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH)

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

An ad to help with our costs